Abstract: β-Lactam antibiotics are frequently used for treatment of multi-drug resistant microbial infections and the most common mechanism of resistance against these antibiotics is bacterial β-lactamase production. Herein, we reported the design, synthesis and in vitro antimicrobial activities of some new 2-substituted-5-(2,4-dinitrophenylsulfonamido)benzoxazole derivatives. Compounds TN1, TN2, and TN3 were found to be significantly active against E. coli isolate which contains extended spectrum β-lactamase enzyme at the MIC value of 8 µg mL -1 and that is 4-fold higher than the reference drug ampicillin. We performed molecular docking studies into active site of Escherichia coli TEM-1 β-lactamase enzyme in order to predict the protein-ligand interactions. According to the docking results, compounds TN1, TN2, and TN3 showed strong interactions between the important active site residues which are responsible for the catalytic mechanism of TEM-1 β-lactamase enzyme and a good correlation is found with the experimental data.
INTRODUCTION
HE need for new effective antimicrobial agents to prevent the diseases caused by the fastest-growing prevalence of multi-drug resistant microbial infections, still maintains its importance. For treatment of these infections β-lactam antibiotics are frequently used and the most common mechanism of resistance against these antibiotics is bacterial β-Lactamase production. The Extended Spectrum β-lactamase (ESBL) are enzymes that produced by Enterobacteriaceae family including Escherichia coli [1] [2] [3] and the enzymes are derived from broad-spectrum beta lactamase TEM-1, TEM-2 or SHV-1 by a limited number of mutations. [4] ESBL enzymes hydrolyze the amide bond of β-lactam ring of penicillins, cephalosporins and related antibiotics, thereby inactivating them and often cause diseases in clinics and hospitals worldwide. [5] Sulbactam, tazobactam, and clavulanate are known as efficient β-lactamase inhibitors however, their efficiency is restricted to class A β-lactamases. [4, 6, 7] Escherichia coli TEM-1 β-lactamase enzyme belongs to class A β-lactamases and have a broad substrate specificity. [8] In recent years, numerous compounds have been reported as β-lactamase inhibitors. Eidam et al. synthesized sulfonamide boronic acid derivatives and reported their higher β-lactamase inhibitory activities. [9] Additionally, a series of phenylethenesulfonamide derivatives found to be the potent inhibitors of TEM-1 β-lactamase enzyme. [10] On the other hand, the benzoxazoles are known as an important class of heterocyclic compounds exhibiting broad spectrum of antimicrobial activities. [11] [12] [13] [14] [15] Herein, we designed and synthesized some new 2-substituted-5-(2,4-dinitrophenylsulfonamido)benzoxazole derivatives, which consist of both benzoxazole and sulfonamide moieties, and tested their in vitro antimicrobial activities. Furthermore we performed molecular docking studies into active site of Escherichia coli TEM-1 β-lactamase enzyme in order to predict their protein-ligand interactions.
11.14 (s, 1H, NH); 13 C NMR (DMSO-d6): d/ppm = 15.09 (CH3), 28.15 (CH2), 111.49, 113.13, 120.24, 120.25, 123.56, 127.20, 127.41, 128.76, 131.68, 132.74, 136.04, 142.10, 147.84, 148.00, 148.54, 150.03, 163.66; ESIMS m/z 469.28 [M+H] + (100); Anal. Calcd. for C21H16N4O7S: C, 53. 84; H, 3.44; N, 11.96; S, 6.84. Found: C, 53.41; H, 3.53; N, 12.04; S, 6 .90. 111.48, 113.13, 120.23, 120.27, 123.31, 127.20, 127.30, 129.92, 131.69, 132.72, 136.01, 142.09, 142.49, 147.84, 148.00, 150.03, 163.67; ESIMS m/z 455.06 [M+H] + (100); Anal. Calcd. for C20H14N4O7S: C, 52.86; H, 3.11; N, 12.33; S, 7.06. Found: C, 53.10; H, 3.44; N, 12.09; S, 6 .95. 64 % yield; m.p 203-205 °C; IR max 3328, 3106, 1530 IR max 3328, 3106, , 1457 IR max 3328, 3106, , 1340 IR max 3328, 3106, , 1148 IR max 3328, 3106, , 1101 111.24, 113.16, 119.94, 120.21, 127.09, 127.17, 128.64, 129.07, 131.64, 132.29, 134.87, 135.99, 141.40, 147.81, 148.23, 150.00, 166.79 ; ESIMS m/z 455.00 [M+H] + (100); Anal. Calcd. for C20H14N4O7S: C, 52.86; H, 3.11; N, 12.33; S, 7.06. Found: C, 52.83; H, 3.40; N, 12.22; S, 6 .99. 46 % yield; m.p 191-192 °C; IR max 3101, 1537 IR max 3101, , 1492 IR max 3101, , 1349 IR max 3101, , 1172 IR max 3101, , 1098 111.19, 113.10, 119.92, 120.14, 127.10, 128.49, 130.99, 131.56, 131.78, 132.24, 133.80, 135.92, 141.27, 147.74, 148.14, 149.94, 166.39 19, 113.09, 119.92, 120.14, 120.26, 127.10, 131.36, 131.43, 131.56, 132.25, 134.21, 135.92, 141.26, 147.74, 148.14, 149.94, 166.32 m.p 192-193 °C; IR max 31110-3037, 1537 IR max 31110-3037, , 1472 IR max 31110-3037, , 1349 IR max 31110-3037, , 1172 IR max 31110-3037, , 1105 113.07, 119.83, 120.13, 127.08, 128.85, 129.11, 131.57, 131.71, 132.19, 135.93, 136.16, 141.34, 147.74, 148.15, 149.93, 166.88 ; ESIMS m/z 469.32 [M+H] + (100); Anal. Calcd. for C21H16N4O7S: C, 53. 84; H, 3.44; N, 11.96; S, 6.84. Found: C, 53.72; H, 3.53; N, 11.97; S, 6 .81. 
2-(4-METHYLPHENYL)-

2-BENZYL-5-(2,4-DINITROPHENYLSULFON-AMIDO)BENZOXAZOLE (TN10)
2-(4-CHLOROBENZYL)-5-(2,4-DINITROPHENYLSULFON-AMIDO)-BENZOXAZOLE (TN11)
2-(4-BROMOBENZYL)-5-(2,4-DINITROPHENYLSULFON-AMIDO)-BENZOXAZOLE (TN13)
61
2-(4-METHYLBENZYL)-5-(2,4-DINITROPHENYLSULFON-AMIDO)-BENZOXAZOLE (TN14)
31 %
Antimicrobial Evaluation
Microdilution Method
Mueller Hinton Agar (MHA), Cation Adjusted Mueller Hinton Broth (CAMHB), Sabouraud Dextrose Agar (SDA), Sabouraud Liquid Medium (SLM) and RPMI-1640 medium with L-glutamine (Sigma) buffered with MOPS (pH7) media were used during the study. Microdilution method was used to determine the susceptibilities of the microorganisms according to the guidelines of Clinical and Laboratory Standards Institute (CLSI) M100-S25 [18] and M27-A3 [19] standards. For bacteria 100 µL of CAMHB for Candida RPMI-1640 medium with L-glutamine buffered with MOPS (pH7) were added to each well of the microplates.
McFarland 0.5 turbidity standard was used to standardize the inoculum density of the microorganisms. Saline suspension of 16-20 hours grown pure colonies of bacteria or fungi were adjusted to achieve McFarland turbidity. The inoculum concentrations resulted in suspensions containing 1-2 × 10 8 CFU mL -1 bacteria. Bacterial inoculum suspensions were diluted 1 : 20 to yield 1 × 10 6 CFU mL -1 and the final suspension in the wells of the microplate was 10 5 CFU mL -1 . Inoculum suspension of Candida albicans was diluted 1: 100 and 1: 20 respectively and 2.5 × 10 3 CFU mL -1 were inoculated to the twofolddiluted solution of the compounds.
Standard powders of ampicillin (Sigma), gentamycin (Sigma), ciprofloxacin (Sigma), meropenem (Sigma) and fluconazole (Sigma) were used as control. Stock solutions of the tested compounds were dissolved in DMSO (Merck). Standard antibiotic solutions were dissolved in appropriate solvents recommended by CLSI guidelines. [18] Antibiotics Diluent Solvent A hundred microliters of the stock solutions of standard drugs and the tested compounds were added to the first wells of the microplates and diluted two-fold in the wells of the microplates. The solution of the synthesized compounds and standard drugs were prepared at 1024, 512, 256, 128, 64, 32, 16, 8 µg mL -1 and 16, 8, 4, 2, 1, 0.5, 0.25, 0 .125 µg mL -1 concentrations, respectively. All solvents and diluents, pure media and pure microorganisms were used in control wells.
Finally, a 10 µL microorganism inoculums were added to each well of the microplates. Bacteria were incubated for 16-20 hours at 37 °C and fungi were incubated for 24-48 hours at 35 °C. After incubation, the lowest concentration of the compounds that completely inhibits macroscopic growth was determined and reported as minimum inhibitory concentrations (MICs).
Molecular Docking
The crystal structure of the TEM-1 β-lactamase enzyme of E. coli was selected for molecular docking studies (PDB ID: 1ERQ). [20] Protein and ligands were prepared by using Accelrys Discovery Studio 3.5 software. [21] Target protein, TEM-1 β-lactamase enzyme was taken, hydrogens were added the ligand was extracted, and optimized using the all atom CHARMm forcefield and the Adopted Basis set Newton Raphson method until the root mean deviation (RMS) gradient was < 0.05 kcal / mol / Å 2 . By using the binding site module, minimized protein was defined as the receptor. The binding site was defined from the cavity finding method and modified that contain all of the important active site residues of the β-lactamase enzyme. Binding sphere (40.78, 36.48, 31.78, 8.27 ) was selected from the active site. The most active compounds against E. coli isolate (TN1, TN2, TN3) and the boronate inhibitor that is the ligand of 1ERQ.pdb crystal structure were sketched, all atom CHARMm forcefield parameterization was assigned and then minimized using the ABNR method as described above. Conformational searches of the ligands were performed using a simulated annealing molecular dynamics approach. The ligands were heated to a temperature of 700 K and then annealed to 200 K. CDOCKER method was performed by using Discovery Studio 3.5. [22] TEM-1 β-lactamase enzyme was held rigid but the ligands were allowed to be flexible during refinement. At first the methodology was validated by docking of boronate inhibitor. The docked position of boronate inhibitor overlaps well with an RMSD of 1.3 Å with the crystal structure position. Afterwards molecular docking studies were performed on the compounds TN1, TN2, TN3. All docked poses were scored by applying Analyze Ligand Poses subprotocol and binding energies were calculated by using in situ ligand minimization step (ABNR method) and using implicit solvent model (GBMV) in Discovery Studio 3.5 software. The lowest binding energy was taken as the best-docked conformation of the compounds for the macromolecule. The pictures were taken by using Discovery Studio 4.1 visualizer.
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RESULTS AND DISCUSSION
Chemistry
In this study, 2-(4-substitutedphenyl/benzyl)-5-(2,4-dinitrophenylsulfonamido)benzoxazole derivatives (TN1-TN14) were synthesized for the first time. At first step, 5-amino-2-substitutedbenzoxazoles were obtained. [14] [15] [16] Then 2,4-dinitrobenzenesulfonyl chloride and 5-amino-2-substitutedbenzoxazole derivatives were treated in pyridine and dichloromethane to obtain 5-(2,4-dinitrophenyl-sulfonamido)benzoxazole derivatives (TN1-TN14) (Scheme 1). [16, 17] Synthesized structures were characterized by 1 H NMR, 13 C NMR, Mass Spectra and Elemental Analysis and the results are in agreement with the proposed structures. According to the 1 H NMR spectra of the compounds the signals of NH (SO2NH) proton of the compounds was observed at 11.05-11.17 ppm. Aromatic CH3 and benzylic CH2 protons were appeared at 2.24-2.40 ppm and 2.71-4.30 ppm, respectively. All the aromatic protons were observed at 7.07-8.39 ppm. 13 C NMR spectra were appropriate to formulas of the synthesized compounds and Mass spectra showed M + + H peaks in accordance with their formulas. Additionally, elemental analyses results of C, H, N, S were found within ± 0.4 % of the calculated amounts.
Scheme 1. Synthetic pathway of 5-(2,4-dinitrophenylsulfon-amido) benzoxazole (TN1-14) derivatives. Reagents and conditions: Pyridine and dichloromethane, RT, 16 h. 
In vitro Antimicrobial Evaluation
All of the synthesized 2-(4-substitutedphenyl/benzyl)- Table 1 .
In vitro biological results demonstrated that all of the synthesized compounds showed a wide spectrum of activity against the tested microorganisms at MIC values between 8 and 512 µg mL -1 . Most of the tested compounds showed significant antibacterial activities against S. aureus, E. faecalis and their drug resistant isolates. Compounds TN5, TN10, TN11 and TN13 showed high antibacterial activity against drug resistant isolate of S. aureus with the MIC value of 16 µg mL -1 and they were found to be 2-fold more effective than all of the reference drugs. Compounds TN2 and TN10 showed better activity than the reference drugs ciprofloxacin, meropenem and gentamycin against drug resistant isolate of E. faecalis with the MIC values of 16-32 µg mL -1 .
Moreover, compounds TN1, TN2 and TN3 showed significant antibacterial activity against E. coli isolate with the MIC value of 8 µg mL -1 and that is 4-fold higher than the reference drug ampicillin. According to obtained data, CH2 bridge which placed on the 2 nd position of benzoxazole ring seems to decrease the activity against E. coli isolate.
Molecular Docking Studies
In this study, compounds TN1, TN2, and TN3 were found to be significantly active at the MIC value of 8 µg mL -1 against E. coli isolate which contains extended spectrum β-lactamase enzyme. Molecular docking studies were performed on these compounds in order to understand the interactions between the compounds and TEM-1 β-lactamase enzyme by using CDOCKER method. [20, 21] TEM-1 is the most common β-lactamase in Gramnegative bacteria, belonging to Class A beta-lactamases 2b group and ampicillin resistance is highly associated with the production of TEM-1 in E. Coli. [4] The active site of TEM-1 β-lactamase enzyme including the residues: Ser70, Lys73, Ser130, Asn132, Glu166, Lys234, Ala237. It is reported that all of these residues play important roles in catalytic mechanism of the β-lactamase enzyme. Ser70 covalently bound to β-lactam ring as an acyl-enzyme intermediate and Lys73 acts as a general base in abstracting a proton from Ser70 and transferring it to the thiazolidine ring of β-lactam antibiotic via Ser130. [23, 24] According to the docking results, boronate inhibitor revealed H bonds with Ser70, Ser130, Asn170, Ala237 and Arg243; revealed pi-alkyl interaction with Tyr105 that are in accordance with the X-ray structure of 1ERQ.pdb. One of the most active compounds TN1 revealed H bonds with Ser130 and Arg243; revealed pi-pi stacking with Tyr105, pi-donor interaction with Asn132, pi-alkyl interaction with Val 216 and Ala237, pi-sulfur interaction with Met270 ( Figure 1b) . TN2 revealed halogen bond with Asn132; revealed pi-alkyl interactions with Pro219, Ala237 and Met270 (Figure 1c) . TN3 revealed H bond with Ser70; revealed pi-pi stacking with Tyr105, pi-alkyl interaction with Val216 and Ala237, pi-sulfur interaction with Met270 ( Figure 1d ). Binding energies of the compounds TN1, TN2, TN3 and boronate inhibitor are -3.60, -2.85, -5.43 and -11.38, respectively (Table 2) . In vitro biological results demonstrated that TN1, TN2 and TN3 exhibited promising antimicrobial activity against E. coli isolate and the docking results were also correlated with the microbiological data. Ser70, Lys73, Tyr105, (a) Ser130 (2.98 Å), Asn132, (c) Glu166, Asn170, Val216, (b) Ser235, Gly236, Ala237, (b) Gly238, Arg243 (2.04 Å), Met270 (d)   TN2 -2,85
Ser70, Lys73, Tyr105, Ser130, Asn132 (x) (3.06 Å), Asn170, Lys215, Val216, Gly218, Pro219, (b) Ala237, (b) Gly238, Met270 (b) TN3 -5.43
Ser70 (2.31 Å), Lys73, Tyr105, (a) Met129, Ser130, Asn132, Glu166, Asn170, Lys215, Val216, (b) Pro219, Ala237, (b] Gly238, Met270 (b) boronate inhibitor -11.38 
